Anteotech Ltd · ASX:ADO
Anteotech — Anteo Diagnostics — Shareholder Meeting (January 2010)
21 slides from Anteotech's shareholder meeting presentation, Jan 22, 2010
Slide 1: Extraordinary General Meeting
For personal use only ANTEO DIAGNOSTICS LTD (ASX:ADO) Extraordinary General Meeting 22nd January 2010 WELCOME
Slide 2: Meeting Format
MEETING FORMAT For personal use only • Introductions • Formal Resolutions • Other Business • Meeting Close • CEO Presentation
Slide 3: Introductions
For personal use only INTRODUCTIONS
Slide 4: Introductions
INTRODUCTIONS For personal use only Anteo Diagnostics Limited • James Henderson – Non Executive Chairman • Richard Martin – Non Executive Director • Dr Geoff Cumming – CEO • Lara Iacusso – Non Executive Director • Joe Maeji – Chief Scientific Officer • Nevin Abernethy – Chief Product Development and
Slide 5: Formal Resolutions
For personal use only FORMAL RESOLUTIONS
Slide 6: Resolutions
RESOLUTIONS For personal use only Resolution 1 – Ratification of Initial Placement Share Issue Resolution 2 – Approval to Issue Balance of Placement Shares Resolution 3 – Approval of the Placement Options
Slide 7: Proxies Received
PROXIES RECEIVED For personal use only Instructions given to validly appointed Proxies in respect of the Resolutions No Resolution For Against Discretionary Abstain Excluded 1 Ratification of Initial Placement 39,092,375 2,300 13,074 500 29,500,000 Share Issue 2 Approval to Issue balance of Placemen
Slide 8: Other Business and Question Time
For personal use only OTHER BUSINESS AND QUESTION TIME
Slide 9: CEO Address – 2010 EGM
For personal use only ANTEO DIAGNOSTICS LTD (ASX:ADO) Better Diagnostics - Faster CEO ADDRESS – 2010 EGM 22nd January 2010
Slide 10: Current Status – Mix&Go
Current Status – Mix&GoTM For personal use only What we have achieved The Future New base Disruptive Proven technology Technology Technology level Identified competitive Signed Licence Benefits of using advantages over current Agreement with Bangs Mix&GoTM will make practices Laboratories this the n
Slide 11: Mix&Go Technology
Mix&GoTM Technology For personal use only Without Mix&GoTM Signal Signal Signal No Signal With Mix&GoTM Signal Signal Signal Signal Impact of Mix&GoTM: = detect disease earlier = more treatment options
Slide 12: Mix&Go Levels the Playing Field
Mix&GoTM Levels the Playing Field For personal use only 21,000 18,000 15,000 Analyte Binding Activity 12,000 9,000 6,000 3,000 - Bead A Bead B Bead A + Mix&Go Bead B + Mix&Go
Slide 13: Mix&Go Improves the Performance of a Bead
Mix&GoTM Improves the Performance of a Bead Commonly Used in For personal use only Diagnostic Immunoassays Immunoassay Analyte IL-6# TSH TNFα α GM-CSF Bead B + 1.3 0.01 3.8 13 Mix&GoTM Bead B 10 0.06 37 1,000 Multiple 8 6 10 76 (times) # Limit of detection values in pg/ml, except TSH (µ µIU/ml)
Slide 14: Why Use Mix&Go
Why Use Mix&GoTM For personal use only • Lower cost to produce existing high volume tests • Improved performance of “difficult” tests • Lower cost and reduced time to market for new tests being developed RESULT: • Increased profits • Increased market share
Slide 15: Mix&Go Features
Mix&GoTM Features For personal use only Need Feature Benefit Performance Improves sensitivity and Increased market share dynamic range Ease of handling Simple, robust process Shortens production time and reduces costs Manufacturing Lower batch-to-batch Reduces production Reproducibility variability
Slide 16: Mix&Go Markets
Mix&GoTM Markets For personal use only Reserch Organisations Bead Manufacturers Uses Mix&GoTM coated beads Coats Bead with Licence Mix&GoTM and Agreement sells coated Mix&GoTM IVD-Pathology beads to end Suppliers users Uses Mix&GoTM coated beads OR Licence Agreement Licences Mix&GoTM directly from A
Slide 17: Mix&Go Markets – Business Models
Mix&GoTM Markets – Business Models For personal use only IVD-Pathology BEAD RESEARCH POINT OF SUPPLIERS MANUFACTURERS ORGANISATIONS CARE Upfront payment Upfront payment Supply of Mix&Go Upfront Supply of Supply of Mix&Go for research and payment Mix&Go for reagent collaboration Research and feasibil
Slide 18: Mix&Go Market Engagement
Mix&GoTM Market Engagement For personal use only Market Signed MTA Signed NDA IVD-Pathology Suppliers 4 6 of top 10 Bead Manufacturers All major bead manufacturers Research Organisations Accessed through Accessed through other segments other segments Point of care 2 of 3 major suppliers Research Ins
Slide 19: Other Mix&Go Applications
Other Mix&GoTM Applications For personal use only • Other (non-human) diagnostic markets – including veterinary and agriculture • Other diagnostic platforms – including biosensors and biochips • In Bioseparations – for example, antibody and streptavidin beads are used in research and in purification
Slide 20: Corporate Snapshot
Corporate Snapshot For personal use only Anteo Diagnostics Limited Capital Structure as at 21st January 2010 Ordinary Shares Currently on Issue 403,595,196 Approval being sought at 22/1/10 EGM 18,833,333 Total Ordinary Shares on Issue post EGM approval 422,428,529 Options Listed Options ("ADOOA") $0
Slide 21: Top Shareholders – Jan 2010
Top 20 Shareholders – 21 Jan 2010 For personal use only Holder Name Balance % Holder Name Balance % Coates Myer & Company Pty 53,762,113 13.3 Merrill Lynch (Australia) 5,143,489 1.3 Limited Nominees Pty Limited <Settle1 A/C> Transocean Securities Pty Ltd 37,742,227 9.4 FCM Finance Pty Ltd 4,702,500
Anteo Diagnostics — Shareholder Meeting (January 2010) on 6ix